
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5325274/publications.pdf Version: 2024-02-01



NACI R KIIMAR

#	Article	IF	CITATIONS
1	Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 2015, 35, S78-S103.	4.3	535
2	Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate, 2011, 71, 985-997.	1.2	273
3	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
4	Green Tea Polyphenols and Cancer Chemoprevention: Multiple Mechanisms and Endpoints for Phase II Trials. Nutrition Reviews, 2004, 62, 204-211.	2.6	182
5	Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochemical Pharmacology, 2003, 66, 965-976.	2.0	161
6	Visceral obesity and breast cancer risk. Cancer, 1994, 74, 632-639.	2.0	142
7	The specific role of isoflavones in reducing prostate cancer risk. Prostate, 2004, 59, 141-147.	1.2	142
8	Complementary Therapies and Integrative Medicine in Lung Cancer. Chest, 2013, 143, e420S-e436S.	0.4	130
9	Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Seminars in Cancer Biology, 2019, 56, 135-148.	4.3	116
10	Curcumin. European Journal of Cancer Prevention, 2012, 21, 407-412.	0.6	105
11	Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prevention Research, 2015, 8, 879-887.	0.7	102
12	The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer, 2002, 94, 1166-1174.	2.0	100
13	Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment. Current Treatment Options in Oncology, 2010, 11, 107-117.	1.3	94
14	Android obesity at diagnosis and breast carcinoma survival. Cancer, 2000, 88, 2751-2757.	2.0	80
15	miRNAs associated with prostate cancer risk and progression. BMC Urology, 2017, 17, 18.	0.6	79
16	Fatigue, Weight Gain, Lethargy and Amenorrhea in Breast Cancer Patients on Chemotherapy: Is Subclinical Hypothyroidism the Culprit?. Breast Cancer Research and Treatment, 2004, 83, 149-159.	1.1	71
17	Obesity and body fat distribution and breast cancer prognosis. Cancer, 1991, 67, 523-528.	2.0	67
18	New Insights Into the Mechanisms of Green Tea Catechins in the Chemoprevention of Prostate Cancer. Nutrition and Cancer, 2012, 64, 4-22.	0.9	67

#	Article	IF	CITATIONS
19	Green tea polyphenols in the prevention of colon cancer. Frontiers in Bioscience - Landmark, 2007, 12, 2309.	3.0	64
20	Racial Differences in the Diagnosis and Treatment of Prostate Cancer. International Neurourology Journal, 2016, 20, S112-119.	0.5	63
21	Obesity, body fat distribution, and sex hormones in breast cancer patients. Cancer, 1991, 67, 2215-2218.	2.0	61
22	Timing of weight gain and breast cancer risk. Cancer, 1995, 76, 243-249.	2.0	60
23	A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer. Nutrition and Cancer, 2007, 59, 163-168.	0.9	55
24	Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infectious Agents and Cancer, 2009, 4, S3.	1.2	53
25	Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget, 2017, 8, 35412-35424.	0.8	53
26	Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget, 2016, 7, 70794-70802.	0.8	41
27	Perioperative Herbal Supplement Use in Cancer Patients: Potential Implications and Recommendations for Presurgical Screening. Cancer Control, 2005, 12, 149-157.	0.7	38
28	Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clinical Medicine Urology [electronic Resource], 2008, 1, CMU.S718.	0.0	38
29	Serum cholesterol reduction with tamoxifen. Breast Cancer Research and Treatment, 1990, 17, 3-7.	1.1	32
30	The value of current nutrition information. Preventive Medicine, 1990, 19, 45-53.	1.6	28
31	Use of Complementary/Integrative Nutritional Therapies during Cancer Treatment: Implications in Clinical Practice. Cancer Control, 2002, 9, 236-243.	0.7	27
32	Tea Consumption and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 341-345.	1.1	26
33	A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. International Journal of Molecular Medicine, 2003, 12, 879-87.	1.8	26
34	Estimate of breast cancer risk reduction with weight loss. Cancer, 1991, 67, 2622-2625.	2.0	24
35	Safety of Purified Isoflavones in Men With Clinically Localized Prostate Cancer. Nutrition and Cancer, 2007, 59, 169-175.	0.9	23
36	Comparing Dietary and Other Lifestyle Factors Among Immigrant Nigerian Men Living in the US and Indigenous Men from Nigeria: Potential Implications for Prostate Cancer Risk Reduction. Journal of Immigrant and Minority Health, 2009, 11, 391-399.	0.8	23

#	Article	IF	CITATIONS
37	Safety and Chemopreventive Effect of Polyphenon E in Preventing Early and Metastatic Progression of Prostate Cancer in TRAMP Mice. Cancer Prevention Research, 2014, 7, 435-444.	0.7	23
38	Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. Society for Integrative Oncology, 2010, 8, 3-13.	0.8	18
39	Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemporary Clinical Trials, 2012, 33, 279-285.	0.8	15
40	Variation in <i>HNF1B</i> and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer, 2013, 2013, 1-7.	0.4	14
41	A Case-Control Study Evaluating the Association of Purposeful Physical Activity, Body Fat Distribution, and Steroid Hormones on Premenopausal Breast Cancer Risk. Breast Journal, 2005, 11, 266-272.	0.4	13
42	Isoflavones in breast cancer chemoprevention: where do we go from here?. Frontiers in Bioscience - Landmark, 2004, 9, 2927.	3.0	11
43	Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families. Cancer, 1993, 71, 2764-2768.	2.0	10
44	A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget, 2020, 11, 1218-1234.	0.8	10
45	Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. Journal of Cancer Science & Therapy, 2012, 01, .	1.7	10
46	Does COVIDâ€19â€related cachexia mimic cancerâ€related cachexia? Examining mechanisms, clinical biomarkers, and potential targets for clinical management. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 519-522.	2.9	9
47	Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget, 2018, 9, 37798-37806.	0.8	9
48	Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget, 2017, 8, 99093-99103.	0.8	8
49	Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of Clinical Trials, 2012, 02, .	0.1	8
50	Chemoprevention in African American Men with Prostate Cancer. Cancer Control, 2016, 23, 415-423.	0.7	5
51	Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Translational Medicine (Sunnyvale, Calif), 2013, 01, 005.	0.4	5
52	Assessment of Malnutrition and Nutritional Therapy Approaches in Cancer Patients. , 2012, , 7-41.		4
53	Cancer Biomarkers for Integrative Oncology. Current Oncology Reports, 2019, 21, 32.	1.8	3
54	Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. Journal of Clinical Trials, 2014, 04, .	0.1	2

#	Article	IF	CITATIONS
55	The Promise of Nutrient-Derived Bioactive Compounds and Dietary Components to Ameliorate Symptoms of Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors. Current Treatment Options in Oncology, 2021, 22, 67.	1.3	2
56	Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genetics: Current Research, 2012, 01, .	0.1	2
57	Green Tea Polyphenols. Evidence - Based Integrative Medicine, 2005, 2, 13-18.	0.2	1
58	Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes and Control, 2013, 24, 1465-1480.	0.8	1
59	Cancer Cachexia (CC). , 2012, , 65-84.		1
60	Cancer Anorexia (CA). , 2012, , 43-64.		1
61	Eicosapentaenoic Acid. Evidence - Based Integrative Medicine, 2004, 1, 189-194.	0.2	0
62	Herbal Supplements and Potential Risk for Surgical Patients. Evidence - Based Integrative Medicine, 2005, 2, 133-137.	0.2	0
63	Green Tea Catechins for Prostate Cancer Chemoprevention. , 0, , .		0
64	Cancer-Related Fatigue (CRF). , 2012, , 131-170.		0
65	Neurocognitive Impairment (NI). , 2012, , 193-219.		0